文献速递糖尿病

禁食及模拟禁食通过激活SIRT1/LXRα减轻糖尿病诱导的全身及微血管功能障碍

Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction.
PubMed 文献 · Diabetologia · 2021-03-26

本研究在db/db小鼠及视网膜内皮细胞中探讨间歇性禁食(IF)、模拟禁食培养条件(FMC)或SRT1720激活SIRT1对糖尿病全身及视网膜代谢、炎症和血管损伤的影响。结果显示IF增加SIRT1表达和活性,FMC通过SIRT1介导LXRα去乙酰化并促进胆固醇外流,SRT1720减轻视网膜炎症并改善视觉功能,提示激活SIRT1信号是糖尿病微血管和骨髓功能障碍的潜在治疗策略。

要点

  • 间歇性禁食上调小鼠肝脏和视网膜Sirt1 mRNA表达并增加视网膜SIRT1活性。
  • 模拟禁食条件通过SIRT1介导LXRα去乙酰化,促进视网膜内皮细胞胆固醇外流。
  • SRT1720激活SIRT1可减轻db/db小鼠视网膜炎症并改善视觉功能损害。

核心结论

  • 通过间歇性禁食或药物激活SIRT1信号是减轻糖尿病微血管和骨髓功能障碍的有效治疗策略。

研究设计与样本

  • 体内使用db/db小鼠模型模拟间歇性禁食,体外使用牛视网膜内皮细胞和大鼠视网膜神经胶质/前体R28细胞系进行24小时血清饥饿。
  • 检测mRNA表达(qPCR)、SIRT1活性(组蛋白去乙酰化酶活性 assay)和LXRα乙酰化(western blot)。

主要发现

  • 间歇性禁食增加小鼠肝脏和视网膜Sirt1 mRNA表达,并增加小鼠视网膜SIRT1活性八倍。
  • 模拟禁食条件增加视网膜内皮细胞SIRT1活性和表达,并使R28细胞Sirt1表达增加两倍。
  • 模拟禁食条件导致SIRT1介导的LXRα去乙酰化,使其活性增加2.4倍(通过Abca1和Abcg1 mRNA表达增加衡量)。
  • 表达组成性乙酰化LXRα突变体的视网膜内皮细胞中上述变化减弱。
  • SRT1720直接激活SIRT1使db/db小鼠视网膜糖尿病诱导的炎症减少两倍,并改善视觉功能损害(通过视网膜电图和视动反应评估),同时预防骨髓糖尿病诱导的髓系增生和降低炎症细胞因子表达。

临床怎么用

  • 间歇性禁食或SIRT1药物激活(如SRT1720)可能作为糖尿病微血管并发症的干预策略。
  • SIRT1/LXR/ABC介导的胆固醇外流是 fasting 健康效益与糖尿病微血管保护之间的机制联系。

局限性

  • 研究主要在动物模型和细胞系中进行,人类临床证据尚缺乏。
  • 间歇性禁食对糖尿病患者的安全性风险尚未完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Homo sapiens evolved under conditions of intermittent food availability and prolonged fasting between meals. Periods of fasting are important for recovery from meal-induced oxidative and metabolic stress, and tissue repair. Constant high energy-density food availability in present-day society contributes to the pathogenesis of chronic diseases, including diabetes and its complications, with intermittent fasting (IF) and energy restriction shown to improve metabolic health. We have previously demonstrated that IF prevents the development of diabetic retinopathy in a mouse model of type 2 diabetes (db/db); however the mechanisms of fasting-induced health benefits and fasting-induced risks for individuals with diabetes remain largely unknown. Sirtuin 1 (SIRT1), a nutrient-sensing deacetylase, is downregulated in diabetes. In this study, the effect of SIRT1 stimulation by IF, fasting-mimicking cell culture conditions (FMC) or pharmacological treatment using SRT1720 was evaluated on systemic and retinal metabolism, systemic and retinal inflammation and vascular and bone marrow damage. METHODS: The effects of IF were modelled in vivo using db/db mice and in vitro using bovine retinal endothelial cells or rat retinal neuroglial/precursor R28 cell line serum starved for 24 h. mRNA expression was analysed by quantitative PCR (qPCR). SIRT1 activity was measured via histone deacetylase activity assay. NR1H3 (also known as liver X receptor alpha [LXRα]) acetylation was measured via western blot analysis. RESULTS: IF increased Sirt1 mRNA expression in mouse liver and retina when compared with non-fasted animals. IF also increased SIRT1 activity eightfold in mouse retina while FMC increased SIRT1 activity and expression in retinal endothelial cells when compared with control. Sirt1 expression was also increased twofold in neuronal retina progenitor cells (R28) after FMC treatment. Moreover, FMC led to SIRT1-mediated LXRα deacetylation and subsequent 2.4-fold increase in activity, as measured by increased mRNA expression of the genes encoding ATP-binding cassette transporter (Abca1 and Abcg1). These changes were reduced when retinal endothelial cells expressing a constitutively acetylated LXRα mutant were tested. Increased SIRT1/LXR/ABC-mediated cholesterol export resulted in decreased retinal endothelial cell cholesterol levels. Direct activation of SIRT1 by SRT1720 in db/db mice led to a twofold reduction of diabetes-induced inflammation in the retina and improved diabetes-induced visual function impairment, as measured by electroretinogram and optokinetic response. In the bone marrow, there was prevention of diabetes-induced myeloidosis and decreased inflammatory cytokine expression. CONCLUSIONS/INTERPRETATION: Taken together, activation of SIRT1 signalling by IF or through pharmacological activation represents an effective therapeutic strategy that provides a mechanistic link between the advantageous effects associated with fasting regimens and prevention of microvascular and bone marrow dysfunction in diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hammer SS, Vieira CP, McFarland D, et al. Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction. Diabetologia. 2021. PMID: 33770194. doi:10.1007/s00125-021-05431-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。